Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML

Leukemia Research

Volumn 27, Issue 2, 2003, Pages 183-191

  Knaust, Eva ^a   Porwit MacDonald, Anna ^b   Gruber, Astrid ^b   Xu, Dawei ^b   Peterson, Curt ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Accumulation and efflux; Cyclosporin A; Daunorubicin; Human AML cells; Metabolic inhibitors

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; BIOACCUMULATION; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA; LEUKEMIA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; REDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CYCLOSPORINE; DAUNORUBICIN; ENZYME INHIBITORS; FEMALE; HUMANS; IODOACETATES; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RNA, MESSENGER; SODIUM AZIDE; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0037296109     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00093-0     Document Type: Article

References (56)

1. List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin. Hematol. 34(4 suppl 5):1997;20-24.
2. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
3. Wood P., Burgess R., MacGregor A., Yin J.A. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br. J. Haematol. 87:1994;509-514.
4. Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchal S., Witz F.et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 85:1995;2147-2153.
5. Del Poeta G., Vendetti A., Aronica G., Stasi R., Cox M.C., Buccisano F.et al. P-glycoprotein expression in de novo acute myeloid leukemia. Leuk. Lymphoma. 27:1997;257-274.
6. Leith C.P., Kopecki K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins mdr1/P-glycoprotein, mrp1, and lrp in acute myeloid leukemia: a southwest oncology group study. Blood. 94:1999;1086-1099.
7. Ford J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer. 32A:1996;991-1001.
8. Vossebeld P.J.M., Sonneveld P. Reversal of multidrug resistance in hematological malignancies. Blood Rev. 13:1999;67-78.
9. Doige C.A., Yu X.H., Sharom F.J. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta. 1146:1993;65-72.
10. Urbatsch I.L., Senior A.E. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch. Biochem. Biophys. 316:1995;135-140.
11. Ueda K., Yoshida A., Amachi T. Recent progress in P-glycoprotein research. Anti-Cancer Drug Des. 14:1999;115-121.
12. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C.et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
13. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357.
14. Scheffer G.L., Wijngaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M.et al. The drug resistance-related protein lrp is the human major vault protein. Nat. Med. 1:1995;578-582.
15. Izquierdo M.A., Scheffer G.L., Flens M.J., Schroeijers A.B., Van der Valk P., Scheper R.J. Major vault protein lrp-related multidrug resistance. Eur. J. Cancer. 32A:1996;979-984.
16. List A.F., Spier C.S., Grogan T.M., Johnson C., Roe D.J., Greer J.P.et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464-2469.
17. Filipits M., Pohl G., Stranzl T., Suchomel R.W., Scheper R.J., Jager U.et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood. 91:1998;1508-1513.
18. Xu D., Areström I., Virtala R., Pisa P., Peterson C., Gruber A. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br. J. Haematol. 106:1999;627-633.
19. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. The mrp expression in acute myeloid leukemia: an update. Adv Exp Med Biol 1999;47:141-50.
20. Legrand O., Simonin G., Zittoun R., Marie J.P. Lung resistance protein (lrp) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia. 12:1998;1367-1374.
21. Tsuji K., Motoji T., Sugawara I., Shiozaki H., Wang Y.H., Motomura S.et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br. J. Haematol. 110:2000;370-378.
22. Filipits M., Suchomel R.W., Zochbauer S., Brunner R., Lechner K., Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res. 3:1997;1419-1425.
23. Hart S.M., Ganeshaguru K., Hoffbrand A.V., Prentice H.G., Metha A.B. Expression of the multidrug resistance-associated protein (mrp) in acute leukaemia. Leukemia. 8:1994;2163-2168.
24. Zhou D.C., Zittoun R., Marie J.P. Expression of multidrug resistance-associated protein (mrp) and multidrug resistance (mdr1) genes in acute myeloid leukemia. Leukemia. 9:1995;1661-1666.
25. Schuurhuis G.J., Broxterman H.J., Ossenkoppele G.J., Baak J.P.A., Eekman C.A., Kuiper C.M.et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/mdr1 and mrp together with 1-b-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin. Cancer Res. 1:1995;81-93.
26. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K.et al. A novel multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15665-15670.
27. Miyake K., Mickley L.A., Litman T., Greenberger L., Zhan Z., Robey R.et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:1999;8-13.
28. Hedley D.W., Xie X.Y., Minden M.D., Choi C.H., Chen H., Ling V. A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia. Leukemia. 11:1997;48-53.
29. Kokenberg E., Sonneveld P., Delwel R., Sizoo W., Hagenbeek A., Löwenberg B. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia. 2:1988;511-517.
30. Marie J.P., Faussat-Suberville A.M., Zhou D., Zittoun R. Daunorubicin uptake by leukemic cells: correlation with treatment outcome and mdr1 expression. Leukemia. 7:1993;825-831.
31. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick G.R.et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 103:1985;626-629.
32. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E.et al. Correlation of multidrug resistance (mdr1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant mdr-/efflux+ and mdr+/efflux- cases. Blood. 86:1995;2329-2346.
33. Broxterman H.J., Sonneveld P., Feller N., Ossekoppele G.J., Währer D.C.R., Eekman C.A.et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 87:1996;4809-4816.
34. Knaust E., Porwit-MacDonald A., Gruber A., Xu D., Peterson C. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin. Haematologica. 85:2000;124-132.
35. Nooter K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeck T., Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int. J. Cancer. 45:1990;263-268.
36. Jiang X.R., Macey M.G., Collins P.W., Newland A.C. Characterization and modulation of drug transport kinetics in K562 cl.6 daunorubicin-resistant cell line. Br. J. Haematol. 86:1994;547-554.
37. Lautier D., Bailly J.D., Demur C., Herbert J.M., Bousquet C., Laurent G. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells. Int. J. Cancer. 71:1997;292-299.
38. An International System for Human Cytogenetic Nomenclature (ISCN). Basel, Karger, 1995. p. 1-114.
39. Wuchter C., Karawajew L., Ruppert V., Schrappe M., Büchner T., Schoch C. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 85:2000;711-721.
40. Harrison C.J. The management of patients with leukaemia: the role of cytogenetics in this molecular era. Br. J. Haematol. 108:2000;19-30.
41. Xie X.Y., Robb D., Chow S., Hedley D.W. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia. 9:1995;1882-1887.
42. Volm M. Multidrug resistance and its reversal. Anticancer Res. 18:1998;2905-2918.
43. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38:1978;1785-1791.
44. Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 kDa membrane protein distinct from P-glycoprotein. Eur. J. Cancer. 29A:1993;408-415.
45. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
46. Damjanovich S., Aszalós A., Mulhern S.A., Szöllösi J., Balázs M., Trón L. Cyclosporin depolarizes human lymphocytes: earliest observed effect on cell metabolism. Eur. J. Immunol. 17:1987;763-768.
47. Jung K., Pergande M. Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. FEBS Lett. 183:1985;167-169.
48. Jung K., Reinholdt C., Sacholz D. Inhibitory effect of cyclosporine on the respiratory efficiency of isolated human kidney mitochondria. Transplantation. 43:1987;162-163.
49. Hokanson J.F., Mercier J.G., Brooks G.A. Cyclosporine A decreases rat skeletal muscle mitochondrial respiration in vitro. Am. J. Respir. Crit. Care Med. 151:1995;1848-1851.
50. Ichas F., Jouaville L.S., Mazat J.P. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell. 89:1997;1145-1153.
51. Hoffman M.M., Wei L.Y., Roepe P.D. Are altered pHi and membrane potential in human mdr1 transfectants sufficient to cause mdr protein-mediated multidrug resistance? J. Gen. Physiol. 108:1996;295-313.
52. Belhoussine R., Morjani H., Sharonov S., Ploton D., Manfait M. Characterization of intracellular pH gradients in human multidrug-resistant tumor cells by means of scanning microspectrofluorometry and dual-emission-ratio probes. Int. J. Cancer. 81:1999;81-89.
53. 4 and structurally related compounds. J. Biol. Chem. 269:1994;27807-27810.
54. Aszalos A., Ross D.D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res. 18:1998;2937-2944.
55. Michieli M., Damiani D., Ermacora A., Raspadori D., Michelutti A., Grimaz S. P-glycoprotein (Pgp) and lung resistance-related protein (lrp) expression and function in leukaemic blast cells. Br. J. Haematol. 96:1997;356-365.
56. Broxterman H.J., Sonneveld P., Pieters R., Lankelma J., Eekman C.A., Loonen A.H. Do P-glycoproterin and major vault protein (MVP/lrp) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia. 13:1999;258-265.